Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
Preclinical evaluation of alpha particle-emitting 213Bi-labeled antibody constructs have demonstrated the specificity and potency of these agents in a variety of cancer systems. The transition of a 213Bi-radiolabeled antibody from a preclinical construct to a clinical drug represented a difficult task that involved development of reliable and validated methods to provide multiple MBq quantities of a pure, immunoreactive agent that met pharmaceutical standards to treat patients.


METHODS
The methods used for the preparation of (213Bi)CHX-A-diethylenetriamine pentaacetic acid (DTPA)-HuM195, an alpha particle-emitting anti-CD33 antibody construct for therapy of myeloid leukemias, is used as a specific example. This article describes methods for reagent purification, drug labeling, radioprotection and chromatographic purification. Quality of the drug is evaluated using radiochemical incorporation and purity assays with instant thin-layer chromatography (ITLC) and high-performance liquid chromatography (HPLC), determination of cell-based antibody total immunereactivity, small animal safety, pyrogen level, sterility and radionuclidic purity.


RESULTS
Sixty-seven doses were prepared. Individual doses ranged from 148 to 814 MBq. Specific activities ranged from 329 to 766 MBq/mg. The radiolabeling efficiency (median +/- SD) of CHX-A-DTPA-HuM195 with 213Bi was 81% +/- 9% (n = 67) after 9 min. The construct was purified by size-exclusion chromatography and was found to be 99% +/- 2% pure (n = 67) by either ITLC or HPLC methods. The immunoreactivity of (213Bi)CHX-A-DTPA-HuM195 was 89% +/- 9% (n = 44) and was independent of the specific activity. The formulated pharmaceutical was found to contain < or =4 +/- 1 EU/mL pyrogens (n = 66); all samples examined were sterile. An 225Ac radionuclidic impurity was present at a level of 0.04 +/- 0.03 x 10(-6)/mL (n = 10) in a product volume of 7.4 +/- 0.5 mL (n = 67). Each of the 67 doses was injected intravenously into patients without complication as part of a phase I clinical trial.


CONCLUSIONS
These data show that 213Bi-labeled antibody constructs can be prepared and administered safely to humans at a wide range of therapeutic levels.
McDevitt
M R
MR
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Finn
R D
RD
Ma
D
D
Larson
S M
SM
Scheinberg
D A
DA
D000186:Actinium / Q000032:analysis; D000465:Algorithms; D000512:Alpha Particles; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001729:Bismuth; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D007553:Isotope Labeling; D007951:Leukemia, Myeloid / Q000276:immunology / Q000532:radiotherapy* / Q000628:therapy; D011786:Quality Control; D011868:Radioisotopes; D063268:Sialic Acid Binding Ig-like Lectin 3
C121884:(213)Bi-CHX-A-diethylenetriamine pentaacetic acid-HuM195; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000970:Antineoplastic Agents; C571163:CD33 protein, human; D011868:Radioisotopes; D063268:Sialic Acid Binding Ig-like Lectin 3; C101579:monoclonal antibody M195; D000186:Actinium; D001729:Bismuth